Dr. Alshaygy on Precision Medicine Research in TGCT

Partner | Cancer Centers | <b>The Tisch Cancer Institute</b>

Ibrahim S. Alshaygy, MD, MSC, discusses precision medicine research in tenosynovial giant cell tumor.

Ibrahim S. Alshaygy, MD, MSC, a clinical fellow in Orthopedic Oncology at Mount Sinai Hospital, discusses precision medicine research in tenosynovial giant cell tumor (TGCT).

Many clinical trials in the United States and Canada are examining the use of targeted therapy for patients with TGCT, especially for those who have exhausted all other medical options, explains Alshaygy. Some of the methods that have been developed to result in tumor size reduction, control disease, and prolong survival in these patients have shown some efficacy and passed through the safety phases of the research process, according to Alshaygy.

Medicine is quickly evolving, and the TGCT field needs to keep up in order to make breakthroughs in the treatment of this patient population, says Alshaygy. Although TGCT is not common, it is important to address the needs of this population, according to Alshaygy.

To this end, additional funding and resources must be contributed to research efforts being made in this field to develop new therapies and modalities to improve and prolong the survival of patients with TGCT, concludes Alshaygy.